Nkarta, Inc. (NKTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.84

From 52W high−22.89%

Volume608788.00

Market cap$202.70M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$2.84

From 52W high

−22.89%

Volume

608788.00

Market cap

$202.70M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

53.3

MomentumView details →

1D Return

+0.71%

YTD Return

+52.43%

SummaryUpdated Jun 1, 2026

Nkarta, Inc. (NASDAQ:NKTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in South San Francisco, California. The company went public in July 2020 and focuses on developing innovative cell therapies for cancer treatment using engineered natural killer (NK) cells. Nkarta represents part of the emerging field of cellular immunotherapy, where immune cells are modified to better recognize and attack cancer cells.

Ask drillr about Nkarta, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−47.36%

ROA (TTM)

−34.75%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−6.08%

FCF YoY

+6.28%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+11.88%

EBITDA YoY

+2.01%

MomentumView details →

1D Return

+0.71%

YTD Return

+52.43%

1Y Return

+41.00%

RSI (14)

53.3

vs 50D SMA

+9.84%

vs 200D SMA

+13.41%

Capital & dividendView details →

Debt/Equity

0.30x

Current Ratio

7.98x

Quick Ratio

7.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.54

EPS Surprise

−49.87%

Beats (12Q)

8/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

−11.04%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−117.32M

Op. CF (TTM)

−92.76M

Next earningsNov 10, 2026 →

Latest newsMore news →

Nkarta reported a wider net loss of $40.37 million for Q2 2026, compared to $22.98 million in the prior-year quarter, due to higher operating expenses and lower other income.40d ago

Similar companies

PepGen Inc.PEPG Oramed Pharmaceuticals Inc.ORMP Coherus Oncology, Inc.CHRS Sol-Gel Technologies Ltd.SLGL Veraxa Biotech Holding AGVRXA Protara Therapeutics, Inc.TARA Find similar companies →

Latest newsMore news →

Nkarta reported a wider net loss of $40.37 million for Q2 2026, compared to $22.98 million in the prior-year quarter, due to higher operating expenses and lower other income.40d ago